Allogene Therapeutics Inc (ALLO) is a biotechnology company focused on the development and commercialization of allogeneic CAR T therapies for the treatment of cancer. Technical analysis can provide valuable insights into the price and volume patterns of the company's stock, helping investors make informed decisions. Let's take a look at some key technical indicators for ALLO.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It ranges from 0 to 100, with readings above 70 indicating overbought conditions and readings below 30 indicating oversold conditions. ALLO's RSI is currently at [value], suggesting [possible trend].

Allogene Therapeutics  (ALLO) Technical Analysis

Allogene Therapeutics Inc (ALLO) stock technical indicators including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Learn about the technical analysis of ALLO stock.

Allogene Therapeutics Inc (ALLO) Technical Analysis: Stock RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	57.22	Neutral	-
auto_graphMACD	16.83	Neutral	317.0%
auto_graphCCI	41.96	Neutral	-12.7%
auto_graphADX	19.11	Neutral	-
auto_graphATR	23.46	Buy	-
auto_graphWILLR	-39.50	Neutral	7.5%
auto_graphROC	10.09	Buy	-99.6%
auto_graphSTOCHRSI	37.32	Neutral	380.4%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Allogene Therapeutics (ALLO) Technical Analysis

Keep an eye on Allogene Therapeutics

Frequently Asked Questions

What are the technical signals for Allogene Therapeutics (ALLO) stock based on the last 30 days?

Take Your Investments to a Whole New Level